- Home
- XHR vs XERS Comparison
XHR vs XERS Comparison
Compare XHR & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XHR
- XERS
- Stock Information
- Founded
- XHR 2007
- XERS 2005
- Country
- XHR United States
- XERS United States
- Employees
- XHR N/A
- XERS N/A
- Industry
- XHR Real Estate Investment Trusts
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- XHR Real Estate
- XERS Health Care
- Exchange
- XHR Nasdaq
- XERS Nasdaq
- Market Cap
- XHR 1.3B
- XERS 1.3B
- IPO Year
- XHR N/A
- XERS 2018
- Fundamental
- Price
- XHR $14.78
- XERS $7.36
- Analyst Decision
- XHR Buy
- XERS Strong Buy
- Analyst Count
- XHR 6
- XERS 7
- Target Price
- XHR $13.83
- XERS $8.00
- AVG Volume (30 Days)
- XHR 844.6K
- XERS 1.9M
- Earning Date
- XHR 10-31-2025
- XERS 11-07-2025
- Dividend Yield
- XHR 3.80%
- XERS N/A
- EPS Growth
- XHR 193.03
- XERS N/A
- EPS
- XHR 0.62
- XERS N/A
- Revenue
- XHR $1,075,161,000.00
- XERS $246,025,000.00
- Revenue This Year
- XHR $3.94
- XERS $43.89
- Revenue Next Year
- XHR $2.87
- XERS $20.40
- P/E Ratio
- XHR $23.79
- XERS N/A
- Revenue Growth
- XHR 4.81
- XERS 35.62
- 52 Week Low
- XHR $8.55
- XERS $2.69
- 52 Week High
- XHR $16.50
- XERS $8.03
- Technical
- Relative Strength Index (RSI)
- XHR 69.53
- XERS 51.35
- Support Level
- XHR $14.05
- XERS $7.56
- Resistance Level
- XHR $14.81
- XERS $7.89
- Average True Range (ATR)
- XHR 0.31
- XERS 0.24
- MACD
- XHR 0.03
- XERS -0.14
- Stochastic Oscillator
- XHR 92.99
- XERS 2.90
About XHR Xenia Hotels & Resorts Inc.
Xenia Hotels & Resorts Inc is a real estate investment trust that invests in premium full-service, lifestyle, and urban upscale hotels and resorts across the United States. The company owns and pursues hotels in the upscale, upper upscale, and luxury segments that are affiliated with various brands. Its hotels are operated by Marriott, along with Hilton, Hyatt, Starwood, Kimpton, Aston, Fairmont, and Loews. The firm's properties are located in various regions across the U.S.: the South Atlantic, West South Central, Pacific, Mountain, and other. Xenia's revenue is divided between room, food and beverage, and other. The firm's customer groups include transient business, group business, and contract business.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).